Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20692218 | 0.85 | ALDH1A1 (0.31) | P2RY1LMNA | |
| SCHEMBL20692199 | 0.85 | ALDH1A1 (0.31) | P2RY1LMNA | |
| SCHEMBL20691463 | 0.79 | POLB (0.48) | NT5EPOLBENPP1P2RY1PDE4D | |
| SCHEMBL14156818 | 0.73 | PNP (0.60) | PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL14156813 | 0.72 | PIM1 (0.48) | PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL24680762 | 0.72 | POLB (0.50) | NT5EPOLBENPP1P2RY1PDE4D | |
| SCHEMBL14064194 | 0.71 | POLB (0.51) | POLBENPP1P2RY1HIF1ATAS1R3 | |
| SCHEMBL20692222 | 0.69 | ALDH1A1 (0.32) | LMNA | |
| SCHEMBL2883759 | 0.69 | NT5E (0.58) | NT5EPOLBENPP1P2RY1 | |
| SCHEMBL14156824 | 0.68 | PIM1 (0.44) | PIM1CSNK2A2CSNK2BCSNK2A1CSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2019-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190030057-A1 | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS | DPYD, NTPCR, CD38 | NT5E 102/4885POLB 30/4885PIM1 2219/4885 |
| US-10744150-B2 | Cyclic dinucleotides as anticancer agents | DPYD, NTPCR, CD38 | NT5E 102/4885POLB 30/4885PIM1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.